El Gouna Film Festival Unveils Highlights of 6th Edition

Marianne Khoury, GFF artistic director, speaks during the press
event. (El Gouna Film Festival).
Marianne Khoury, GFF artistic director, speaks during the press event. (El Gouna Film Festival).
TT

El Gouna Film Festival Unveils Highlights of 6th Edition

Marianne Khoury, GFF artistic director, speaks during the press
event. (El Gouna Film Festival).
Marianne Khoury, GFF artistic director, speaks during the press event. (El Gouna Film Festival).

El Gouna Film Festival (GFF) unveiled the highlights of its sixth edition set to be held from 13 to 20 October. In a press event on Monday, the festival announced it is hosting a “film market”, for the first time, in addition to several new initiatives including the “CineGouna Emerge”.

The festival returns after a one-year hiatus, which according to Intishal al-Timimi, director of GFF, didn’t affect it, but highlighted its importance on the cinematic scene. He also noted that the void the festival left and its comeback reflected the success of its past five editions, and the sturdy foundations on which it stood since its debut in 2017.

Timimi said he’s committed to maintaining the power of GFF despite the serious competition among the Arabic film festivals, which start with the Gouna festival and ends with the Red Sea Film Festival separated by short time intervals.

This year, the Feature Narrative Competition includes 14 films. The jury of the competition is headed by Bosnian Director Jasmila Žbanić.

The GFF program also includes 12 films in the Feature Documentary Competition, 21 films in the Short Film Competition, and 17 films in the Official Selection Out of Competition section.

Also, 13 films compete for the GFF's annual Cinema for Humanity Audience Award, while five compete for El Gouna Green Star Award dedicated to the best work covering environmental causes.

Eng. Naguib Sawiris, the festival founder, said “the city of Gouna is the key behind the festival’s success. Cinema makes happiness and we need that,” noting that he’s passionate about movies and that he watches four films a day. Sawiris said the festival has succeeded since its first edition thanks to good intentions and teamwork.

Marianne Khoury, GFF artistic director, announced that 80 films are partaking in the festival, some of them won international awards. She also said that the festival received a total of 160 submissions, and the committee selected 20 projects — 13 in development and 7 in post-production, adding that 14 films will be screened simultaneously with the GFF as part of the “Zawya Cinema”, so the audience in Cairo can watch them. Yousra, the esteemed actress and member of the International Advisory Committee, called on the media to give the festival’s major segments, workshops and events the same attention usually given to the Red Carpet.

Amr Mansi, GFF executive director, said he is betting on a different edition that serves the cinema industry and puts it on par with tourism. “We were concerned about the economic situation and the lack of sponsor, but we saw a remarkable enthusiasm from the old sponsors and those who have joined as for the first time,” he added.

The press event was also attended by filmmaker Marwan Hamed, who will be handed the 2023 Career Achievement Award; and filmmaker Amr Salamah who partakes in the festival with his film “60 Pound” in the short film competition. El Gouna Film Bridge includes a panel with artist Hend Sabry, and a lecture on production with American producer Ted Hope, in addition to a number of discussion panels on topics like influential filmmaking, storytelling and climate, and the Egyptian cinema.



Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
TT

Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP

It's been dubbed the "Arc de Trump." But now President Donald Trump's latest building project has an official name -- the "United States Triumphal Arch."

White House Press Secretary Karoline Leavitt revealed the formal title on Wednesday, saying the giant structure was being built to mark the 250th anniversary of US independence, AFP reported.

"In honor of this historic occasion, President Trump and the Department of Interior will submit plans for the United States Triumphal Arch," Leavitt told reporters.

Showing off a picture that she initially held upside down, Leavitt said the "monumental" arch would stand 250 feet (76.2 meters) tall "in honor of 250 years."

Its colossal height, including a huge golden Lady Liberty statue on top, means it will dwarf perhaps its most famous predecessor, the Arc de Triomphe in Paris, which stands at 164 feet.

In fact it is set to be the largest structure of its kind in the world, pipping Mexico City's Monument to the Revolution and knocking Pyongyang's Arch of Triumph to third place.

Plans for the arch were first revealed in October when AFP journalists spotted a model on Trump's desk in the Oval Office, after which it was quickly dubbed the "Arc de Trump" by US media.

Trump revealed the first full renderings for the structure last Friday.

The arch is one of several architectural projects -- including the construction of a gigantic White House ballroom and renovations to the Kennedy Center for the Performing Arts -- that Trump has undertaken to leave a mark on Washington in his second term.

Critics say the gold-accented arch, which will tower over the 99-foot-tall Lincoln Memorial, is a monument to the 79-year-old Trump's vanity.

The arch will partly be funded by US taxpayers, getting $2 million in special funds from the US National Endowment for the Humanities, with up to $13 million in funds to match any donations, ABC News reported.

But Leavitt said it was aimed at celebrating US national pride.

"Long after everyone in this room is gone, our children and grandchildren will remain inspired by this national monument," she told reporters.


Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
TT

Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.

The review by the Cochrane organization -- which is considered the gold standard for analyzing existing evidence -- looked at drugs that target a plaque called amyloids which builds up in the brains of Alzheimer's patients.

Researchers have long sought a way to eliminate this plaque, believing it could be the cause of the most common form of dementia which affects millions of elderly people every year, said AFP.

After decades of costly yet unsuccessful research, two anti-amyloid drugs called lecanemab and donanemab were initially hailed as gamechangers that finally offered a way to slow the progress of the debilitating disease.

Both drugs were approved by the United States and European Union over the last few years.

However concerns about their effectiveness, cost and side effects including an increased risk of brain swelling and bleeding have since prompted caution. State-run health services in the UK and France have refused to cover the drugs.

The new Cochrane review combined data from 17 clinical trials that included a total of more than 20,000 people with mild cognitive impairment or early dementia.

The trials, which took place over roughly 18 months, studied seven different anti-amyloid drugs.

Only one of the trials examined donanemab -- sold under the name Kisunla by US pharma giant Eli Lilly -- while one studied lecanemab, sold as Leqembi by Biogen and Eisai.

While early trials suggested these drugs made a statistically significant difference, this did not translate into "something clinically meaningful for patients," lead study author Francesco Nonino of Italy's IRCCS institute told a press conference.

Brain scans showed that the drugs successfully removed amyloids, the researchers emphasized.

This means "the idea that removing amyloids will benefit patients was refuted by our results," said study co-author Edo Richard of Radboud University Medical Center in the Netherlands.

- 'Not delivering on promise' -

Richard, who has previously expressed skepticism about anti-amyloid drugs, said he hopes efforts targeting other mechanisms that potentially cause Alzheimer's lead to more effective drugs in the future.

British biologist John Hardy, who first developed the amyloid hypothesis in the 1990s, criticized the review for lumping together data about lecanemab and donanemab along with drugs that are known to be ineffective, therefore dragging down the overall average.

"This is a silly paper which should not have been published," Hardy told AFP, disclosing that he has consulted for Eli Lilly, Biogen and Eisai.

In response to such questions, Richard said that while the drugs included in the study may work in different ways, they all have the same target: amyloid beta proteins.

Australian neuroscientist Bryce Vissel, who was not involved in the research, said it "does not prove amyloid has no role in Alzheimer's, and it does not rule out future amyloid-directed therapies that may yet help patients".

"But it does show that the current generation of anti-amyloid drugs is not delivering the promise that has surrounded it."


Indonesia Police Arrest Six for Komodo Dragon Smuggling

A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
TT

Indonesia Police Arrest Six for Komodo Dragon Smuggling

A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)

Indonesian authorities said Wednesday they have arrested six people allegedly involved in smuggling endangered Komodo dragons native to the archipelago and destined for Thailand.

Two suspects were arrested in February in the port city of Surabaya on the east coast of Java island as they got off a ship with three live Komodo dragons -- the world's largest living lizard.

Further investigation led to four more arrests in the weeks that followed, AFP reported.

Police said the animals had been obtained from "suppliers or hunters" in Indonesia's East Nusa Tenggara province, where they are native to a handful of small islands.

The suspects are accused of buying the dragons for 5.5 million rupiah (about $320) apiece and selling them for six times the price, apparently to be shipped to clients in Thailand.

According to East Java police, the suspects have smuggled and traded at least 20 Komodo dragons since January last year, and pocketed some $33,000.

They face up to five years in prison and a fine.

The International Union for Conservation of Nature lists the Komodo dragon as endangered, with a global population of about 3,400, including juveniles.

The fearsome reptiles, which can grow to three meters (10 feet) in length and weigh up to 90 kilograms (200 pounds), are threatened by human activity and by climate change destroying their habitat.

Poachers collect them to be sold as pets or display animals.

Komodo dragons in the wild are found only in Indonesia's World Heritage-listed Komodo National Park and on neighboring Flores island.

Police said Wednesday they had also arrested two suspects for smuggling 140 kilograms of pangolin scales from the northwestern province of Riau to Surabaya.

Pangolins are among the world's most endangered species, and their scales are prized in countries like China and Vietnam, where they are used in traditional remedies even though they provide no scientifically proven medicinal benefit.